Recruiting
Phase 2

Sirolimus

Sponsor:

Darcy Krueger

Code:

NCT05104983

Conditions

Tuberous Sclerosis Complex

Epilepsy

Eligibility Criteria

Sex: All

Age: 0

Healthy Volunteers: Not accepted

Interventions

Sirolimus

Placebo

Study Details

Brief summary:

This trial is a Phase II randomized, double-blind, placebo controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in TSC infants.

This study is supported by research funding from the Office of Orphan Products Division (OOPD) of the US Food and Drug Administration (FDA).

Conditions

Tuberous Sclerosis Complex

Epilepsy

Study ID

NCT05104983

Start date

Oct 13, 2021

Status verified date

Jan, 2026

Completion date

Jun 30, 2027

Anticipated

Primary completion date

Jun 30, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. 0-6 months of age at the time of enrollment (subject must be <7 months of chronological age at time of randomization and treatment initiation). Corrected age must be at least 39 weeks (calculated by subtracting the number of weeks born before 40 weeks gestation from the chronological age).
2. Has a confirmed diagnosis of TSC based on established clinical or genetic criteria

Exclusion Criteria:

1. Prior history of seizures (clinical or electrographic) at the time of enrollment or identified on baseline EEG.
2. Has been treated in the past or is currently being treated at the time of enrollment with conventional anticonvulsant medications (AEDs), systemic (oral) mTOR inhibitors (such as rapamycin, sirolimus, or everolimus), ketogenic-related special diet, or another anti-seizure therapeutic agent, device, or procedure.
3. Has taken any other investigational drug as part of another research study, within 30 days prior to the baseline screening visit.
4. Has a significant illness or active infection at the time of the baseline screening visit
5. Has a history of significant prematurity, defined as gestational age <30 weeks at the time of delivery, or other significant medical complications at birth or during the neonatal period that other than TSC would convey additional risk of seizures or neurodevelopmental delay (i.e. HIE, severe neonatal infection, major surgery, prolonged ventilatory or other life-saving supportive care or procedures).
6. Abnormal laboratory values at baseline (i.e., renal function, liver function, or bone marrow production) that are in the opinion of the investigator clinically significant and may jeopardize the safety of the study subject.
7. Prior, planned or anticipated neurosurgery within 3 months of the baseline visit
8. Has a TSC-associated condition for which mTOR treatment is clinically indicated (i.e. SEGA or AML).
9. Subjects who are, in the opinion of the investigator, unable to comply with the requirements of the study.

Study Design

Enrollment

64 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: Sirolimus

Sirolimus

placebo comparator: Placebo

Placebo

Interventions

Sirolimus

The investigational drug product to be used in this study is sirolimus, provided in oral suspension.

Placebo

Matching placebo

Primary outcome measure

  • Efficacy -- time to seizure onset [ Time Frame: 12 months of age ]
  • Safety -- adverse events [ Time Frame: 12 months of age ]

Central Contacts and Locations

Central contacts

Molly S Griffith, BA

513-636-9669info@tscsteps.org

Jessica Krefting, RN

256-533-0833info@tscsteps.org

Locations

University of Alabama at Birmingham

Recruiting

Birmingham, Alabama, United States, 35294

Principal Investigator:

E. Martina Bebin, MD, MPA

University of California at Los Angeles

Recruiting

Los Angeles, California, United States, 90095

Principal Investigator:

Rajsekar Rajamaran, MD, MS

Stanford University

Recruiting

Palo Alto, California, United States, 94304

Contacts

Rayann Solidum

rsolidum@stanford.edu

Principal Investigator:

Brenda Porter, MD

Children's Hospital Colorado

Recruiting

Aurora, Colorado, United States, 80045

Contacts

Principal Investigator:

Kevin Ess, MD

Lurie Children's Hospital of Chicago

Recruiting

Chicago, Illinois, United States, 60611

Contacts

Principal Investigator:

Tracy Gertler, MD

Boston Children's Hospital

Recruiting

Boston, Massachusetts, United States, 02115

Principal Investigator:

Mustafa Sahin, MD, PhD

Washington University -- St. Louis

Recruiting

St Louis, Missouri, United States, 63110

Principal Investigator:

Michael Wong, MD, PhD

Cincinnati Children's Hospital Medical Center

Recruiting

Cincinnati, Ohio, United States, 45229

Contacts

Molly S Griffith, BA

513-636-9669info@tscsteps.org

Principal Investigator:

Darcy A Krueger, MD, PhD

University of Texas HSC at Houston

Recruiting

Houston, Texas, United States, 77030

Principal Investigator:

Hope Northrup, MD

Seattle Children's Hospital

Recruiting

Seattle, Washington, United States, 98105

Principal Investigator:

Stephanie Randle, MD

More Information

Sponsor

Darcy Krueger

Last update posted

Jan 22, 2026

Last verified

Jan, 2026

Keywords

  • Tuberous Sclerosis Complex
  • TSC
  • epilepsy
  • prevention
  • mTOR
  • sirolimus
  • infant

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Darcy Krueger on 2026-01-22.